NCT02017912View on ClinicalTrials.gov

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

July 31, 2016

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
BIOLOGICAL

Nurown MSC-NTF cells

Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration

BIOLOGICAL

Placebo

Excipient administration by combined intramuscular and intrathecal administration

Trial Locations (3)

55905

Mayo Clinic, Rochester

02115

Massachusetts General Hospital, Boston

01655

UMass Medical School, Worcester

Sponsors
All Listed Sponsors
lead

Brainstorm-Cell Therapeutics

INDUSTRY